

Naga Chalasani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8310693/publications.pdf>

Version: 2024-02-01

186
papers

22,701
citations

34105

52
h-index

8630

146
g-index

188
all docs

188
docs citations

188
times ranked

22355
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 115-124.e7.	4.4	25
2	Eight-Fold Increase in Dietary Supplement-Related Liver Failure Leading to Transplant Waitlisting Over the Last Quarter Century in the United States. <i>Liver Transplantation</i> , 2022, 28, 169-179.	2.4	14
3	Patient-Reported Outcome Measures Modestly Enhance Prediction of Readmission in Patients with Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1426-e1437.	4.4	8
4	Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. <i>Annals of Surgery</i> , 2022, 275, e174-e180.	4.2	11
5	Attendance at a Transitional Liver Clinic May Be Associated with Reduced Readmissions for Patients with Liver Disease. <i>American Journal of Medicine</i> , 2022, 135, 235-243.e2.	1.5	4
6	High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. <i>Hepatology</i> , 2022, 75, 1491-1506.	7.3	99
7	Severe Alcohol-Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure. <i>Hepatology Communications</i> , 2022, 6, 1090-1099.	4.3	7
8	Health-related quality of life is dynamic in alcoholic hepatitis and responds to improvement in liver disease and reduced alcohol consumption. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 252-261.	2.4	3
9	Liver Transplantation in Recipients With Class III Obesity: Posttransplant Outcomes and Weight Gain. <i>Transplantation Direct</i> , 2022, 8, e1242.	1.6	4
10	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. <i>Journal of Hepatology</i> , 2022, 76, 832-840.	3.7	16
11	Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. <i>Journal of Hepatology</i> , 2022, 77, 108-115.	3.7	17
12	Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 464-473.	1.6	1
13	Unexplained liver test elevations after SARS-CoV-2 vaccination. <i>Journal of Hepatology</i> , 2022, 77, 251-253.	3.7	7
14	Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist. <i>Journal of Viral Hepatitis</i> , 2022, 29, 366-374.	2.0	13
15	Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications. <i>American Journal of Gastroenterology</i> , 2022, 117, 1089-1096.	0.4	4
16	Neighborhood poverty is associated with failure to be waitlisted and death during liver transplantation evaluation. <i>Liver Transplantation</i> , 2022, 28, 1441-1453.	2.4	15
17	PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features. <i>Hepatology</i> , 2022, 76, 1482-1494.	7.3	9
18	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20

#	ARTICLE	IF	CITATIONS
19	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	21.4	68
20	Letter: noninvasive prediction models to exclude cirrhosis in <sc>NAFLD</sc> â€”not everyone fits the mould. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 182-183.	3.7	0
21	Changes in Serum Myostatin Levels in Alcoholic Hepatitis Correlate with Improvement in MELD. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3062-3073.	2.3	2
22	Fatty Liver Disease in Human Immunodeficiency Virusâ€”Hepatitis B Virus Coinfection: A Cause for Concern. <i>Clinical Infectious Diseases</i> , 2021, 73, e3286-e3287.	5.8	2
23	Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1292-1293.e3.	4.4	22
24	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165.	3.2	19
25	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	4.4	25
26	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liverâ€”Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	7.3	20
27	Sex disparities in waitlisting and liver transplant for acute liver failure. <i>JHEP Reports</i> , 2021, 3, 100200.	4.9	9
28	Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. <i>Liver International</i> , 2021, 41, 996-1011.	3.9	16
29	Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis. <i>FEMS Microbiology Letters</i> , 2021, 368, .	1.8	16
30	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. <i>Journal of Clinical Lipidology</i> , 2021, 15, 275-291.	1.5	8
31	Blood Biomarkers of Intestinal Epithelium Damage Regenerating Isletâ€”derived Protein 3Î± and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 720-731.	2.4	5
32	Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G439-G449.	3.4	18
33	Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcoholâ€”Associated Hepatitis. <i>Hepatology</i> , 2021, 74, 2436-2451.	7.3	15
34	Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status. <i>Liver International</i> , 2021, 41, 2703-2711.	3.9	6
35	Saroglitazar, a PPARâ€”Î³ Agonist, for Treatment of NAFLD: A Randomized Controlled Doubleâ€”Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	7.3	163
36	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , 2021, 239, 161-167.e5.	1.8	8

#	ARTICLE	IF	CITATIONS
37	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00400.	2.5	12
38	Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. <i>American Journal of Gastroenterology</i> , 2021, 116, 994-1006.	0.4	30
39	Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome. <i>Journal of Clinical Lipidology</i> , 2021, 15, 805-813.	1.5	3
40	Karnofsky performance status predicts outcomes in candidates for simultaneous liver–kidney transplant. <i>Clinical Transplantation</i> , 2021, 35, e14190.	1.6	5
41	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00420.	2.5	6
42	Vitamin E Improves Transplant–Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 495-509.	7.3	117
43	Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 477-485.e5.	4.4	55
44	Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father–Son Pair With Advanced Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 383-385.	7.3	4
45	Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. <i>Drug Safety</i> , 2020, 43, 281-290.	3.2	3
46	Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. <i>BMC Gastroenterology</i> , 2020, 20, 4.	2.0	14
47	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	1.3	203
48	Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 251-261.	0.4	58
49	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug–induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 90-109.	3.7	21
50	An Open–Label, Dose–Escalation Study to Assess the Safety and Efficacy of IL–22 Agonist F–652 in Patients With Alcohol–Associated Hepatitis. <i>Hepatology</i> , 2020, 72, 441-453.	7.3	107
51	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1486-1495.	0.4	27
52	Incidence and Risk Factors of Recurrent <i>Clostridioides difficile</i> Infection in Patients With Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00189.	2.5	5
53	Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 302.	2.0	5
54	Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States: A Nationwide Assessment. <i>American Journal of Gastroenterology</i> , 2020, 115, 1849-1856.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Association of State Medicaid Expansion With Racial/Ethnic Disparities in Liver Transplant Wait-listing in the United States. <i>JAMA Network Open</i> , 2020, 3, e2019869.	5.9	22
56	Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis. <i>American Journal of Medicine</i> , 2020, 133, 1479-1487.e2.	1.5	11
57	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2980-2988.e4.	4.4	19
58	Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 785-785.	7.3	0
59	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	1.3	15
60	Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00139.	2.5	4
61	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. <i>Annals of Diagnostic Pathology</i> , 2020, 47, 151518.	1.3	37
62	Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2305-2314.e12.	4.4	38
63	Treatment of Idiosyncratic Drug-Induced Liver Injury Using Steroids. <i>ACG Case Reports Journal</i> , 2020, 7, e00319.	0.4	7
64	A PNPLA3 I148M gene-edited Ossabaw swine model of Nonalcoholic steatohepatitis (NASH). <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	1
65	Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00288.	2.5	9
66	Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2651-2653.	4.4	3
67	Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e196412.	5.9	56
68	Black Adult Patients With Acute Liver Failure Are Sicker and More Likely to Undergo Liver Transplantation Than White Patients. <i>Liver Transplantation</i> , 2019, 25, 1634-1641.	2.4	11
69	Letter: metformin treatment and hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 836-837.	3.7	0
70	Clinical characteristics and outcomes of mild to moderate alcoholic hepatitis. <i>GastroHep</i> , 2019, 1, 161-165.	0.6	6
71	Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 838-839.	3.7	0
72	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	3.7	77

#	ARTICLE	IF	CITATIONS
73	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	30.5	409
74	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	5.9	230
75	Long-term metformin use may improve clinical outcomes in diabetic patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	3.7	52
76	Relationship between resolution of nonalcoholic steatohepatitis and changes in lipoprotein subfractions: a posthoc analysis of the PIVENS trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1205-1213.	3.7	24
77	Reply. <i>Hepatology</i> , 2019, 70, 752-752.	7.3	0
78	Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2645-2652.	2.3	10
79	Expanding the Donor Pool With the Use of Extended Criteria Donation After Circulatory Death Livers. <i>Liver Transplantation</i> , 2019, 25, 1198-1208.	2.4	54
80	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
81	Reply. <i>Hepatology</i> , 2019, 70, 445-446.	7.3	0
82	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. <i>BMJ Open</i> , 2019, 9, e023597.	1.9	38
83	Novel HLA Class I Alleles Outside the Extended DR3 Haplotype Are Protective against Autoimmune Hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00032.	2.5	5
84	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-Induced Liver Injury in American Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 152-159.	1.8	21
85	Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography?. <i>American Journal of Gastroenterology</i> , 2019, 114, 995-997.	0.4	15
86	Alcohol Abstinence Does Not Fully Reverse Abnormalities of Mucosal-Associated Invariant T Cells in the Blood of Patients With Alcoholic Hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00052.	2.5	26
87	Advice Regarding Alcohol Use by Individuals With Nonalcoholic Fatty Liver Disease: Primum non nocere. <i>Hepatology</i> , 2019, 69, 9-11.	7.3	1
88	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NCT0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019, 27, 59-67.	3.0	18
89	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	4.4	322
90	Patients With Chronic Liver Disease Suggestive of Nonalcoholic Fatty Liver Disease May Be at Higher Risk for Drug-Induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2814-2815.	4.4	40

#	ARTICLE	IF	CITATIONS
91	Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1705-1710.	2.3	8
92	Lipid mediators of liver injury in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G75-G81.	3.4	42
93	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019, 69, 1287-1299.	7.3	45
94	Relationship between three commonly used noninvasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	3.9	47
95	Oxidized Derivatives of Linoleic Acid in Pediatric Metabolic Syndrome: Is Their Pathogenic Role Modulated by the Genetic Background and the Gut Microbiota?. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 241-250.	5.4	30
96	The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth. <i>American Journal of Gastroenterology</i> , 2018, 113, 376-383.	0.4	50
97	Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. <i>Hepatology International</i> , 2018, 12, 97-106.	4.2	19
98	A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis. <i>Abdominal Radiology</i> , 2018, 43, 2190-2197.	2.1	8
99	Concomitant Psychiatric and Nonalcohol-Related Substance Use Disorders Among Hospitalized Patients with Alcoholic Liver Disease in the United States. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 397-402.	2.4	22
100	Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 722-729.e2.	4.4	27
101	Drug-induced chronic liver injury. <i>Journal of Hepatology</i> , 2018, 69, 248-250.	3.7	10
102	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	7.3	4,738
103	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 189-199.	2.1	24
104	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	7.3	192
105	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. <i>Journal of Hepatology</i> , 2018, 68, 305-315.	3.7	427
106	Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1101-1108.	2.4	30
107	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	1.3	536
108	Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. <i>Epigenetics</i> , 2018, 13, 605-626.	2.7	13

#	ARTICLE	IF	CITATIONS
109	Lower expression of tumor microRNA miR-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. <i>Journal of Surgical Oncology</i> , 2018, 118, 431-439.	1.7	6
110	Posttraumatic Stress Disorder in Patients with Heavy Alcohol Consumption and Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1933-1938.	2.4	12
111	Drug-Induced Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2018, 17, 260-269.	0.9	1
112	Dynamic mTORC1-TFEB feedback signaling regulates hepatic autophagy, steatosis and liver injury in long-term nutrient oversupply. <i>Autophagy</i> , 2018, 14, 1779-1795.	9.1	53
113	Common variation near IRF6 is associated with IFN- γ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	21.4	32
114	Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension – “The Devil Is in the Details”. <i>Hepatology</i> , 2018, 68, 2438-2440.	7.3	32
115	Automated assessment of steatosis in murine fatty liver. <i>PLoS ONE</i> , 2018, 13, e0197242.	2.5	18
116	Hospital Readmissions in Patients with Cirrhosis: A Systematic Review. <i>Journal of Hospital Medicine</i> , 2018, 13, 490-495.	1.4	49
117	Leveraging Social Networking Sites for an Autoimmune Hepatitis Genetic Repository: Pilot Study to Evaluate Feasibility. <i>Journal of Medical Internet Research</i> , 2018, 20, e14.	4.3	20
118	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 103-112.e2.	4.4	144
119	Most Individuals With Advanced Cirrhosis Have Sleep Disturbances, Which Are Associated With Poor Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1271-1278.e6.	4.4	55
120	Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study. <i>Hepatology</i> , 2017, 66, 575-590.	7.3	29
121	Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1521-1528.	4.4	109
122	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , 2017, 67, 137-144.	3.7	100
123	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017, 187, 141-146.e1.	1.8	91
124	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
125	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	21.4	230
126	Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1630-1637.	2.3	30

#	ARTICLE	IF	CITATIONS
127	Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. <i>American Journal of Gastroenterology</i> , 2017, 112, 1382-1388.	0.4	55
128	Acute Alcoholic Hepatitis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 37-48.	2.4	18
129	Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. <i>Hepatology</i> , 2017, 65, 1762-1764.	7.3	33
130	Profiles of miRNA in serum in severe acute drug induced liver injury and their prognostic significance. <i>Liver International</i> , 2017, 37, 757-764.	3.9	49
131	Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2017, 12, e0185813.	2.5	9
132	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1845-1846.	4.4	4
133	Febuxostat-induced acute liver injury. <i>Hepatology</i> , 2016, 63, 1047-1049.	7.3	26
134	Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1790-1792.	2.3	2
135	Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?. <i>Gastroenterology</i> , 2016, 151, 1046-1051.	1.3	38
136	Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1831-1838.e3.	4.4	50
137	Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1189-1195.e1.	4.4	71
138	Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. <i>Journal of Clinical Oncology</i> , 2016, 34, e9-e12.	1.6	27
139	Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2016, 64, 1211-1213.	3.7	21
140	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016, 9, 26-40.	3.1	11
141	Chronic liver injury induced by drugs: a systematic review. <i>Liver International</i> , 2015, 35, 2343-2353.	3.9	83
142	Discrepancies in Liver Disease Labeling in the Package Inserts of Commonly Prescribed Medications. <i>Gastroenterology</i> , 2015, 148, 269-273.	1.3	14
143	Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 3867-3872.	0.6	80
144	Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3642-3646.	2.3	12

#	ARTICLE	IF	CITATIONS
145	The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. <i>Gastroenterology</i> , 2015, 149, 278-281.	1.3	59
146	Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. <i>Human Pathology</i> , 2015, 46, 767-775.	2.0	33
147	Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle. <i>Diabetes</i> , 2015, 64, 3321-3327.	0.6	17
148	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015, 148, 1340-1352.e7.	1.3	646
149	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 338-348.	3.6	27
150	Clinical and Histologic Features of Azithromycin-Induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 369-376.e3.	4.4	95
151	Liver Injury and Fibrosis Induced by Dietary Challenge in the Ossabaw Miniature Swine. <i>PLoS ONE</i> , 2015, 10, e0124173.	2.5	22
152	Genetic Polymorphism of Cytochrome P450 4F2, Vitamin E Level and Histological Response in Adults and Children with Nonalcoholic Fatty Liver Disease Who Participated in PIVENS and TONIC Clinical Trials. <i>PLoS ONE</i> , 2014, 9, e95366.	2.5	35
153	Drug-Induced Hepatic Steatosis. <i>Seminars in Liver Disease</i> , 2014, 34, 205-214.	3.6	80
154	Slow but Steady Progress in a Field with Many Knowledge Gaps. <i>Seminars in Liver Disease</i> , 2014, 34, 113-114.	3.6	13
155	Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1550-1555.	4.4	32
156	An assessment by the Statin Liver Safety Task Force: 2014 Update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S47-S57.	1.5	189
157	Trials and Tribulations in Drug Development for Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2104-2105.	4.4	4
158	Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1077-1084.	4.4	36
159	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2121-2130.e2.	4.4	97
160	HIV-1 Coinfection Profoundly Alters Intrahepatic Chemokine but Not Inflammatory Cytokine Profiles in HCV-Infected Subjects. <i>PLoS ONE</i> , 2014, 9, e86964.	2.5	9
161	Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). <i>Hepatology International</i> , 2013, 7, 755-764.	4.2	60
162	Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis. <i>Annals of Internal Medicine</i> , 2012, 156, 857.	3.9	47

#	ARTICLE	IF	CITATIONS
163	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	1.3	1,486
164	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826.	0.4	359
165	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	7.3	2,935
166	Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. <i>Hepatology International</i> , 2012, 6, 379-385.	4.2	106
167	Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2011, 55, 654-659.	3.7	260
168	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1659.	7.4	926
169	Risk Factors for Idiosyncratic Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2010, 138, 2246-2259.	1.3	295
170	Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2010, 139, 1567-1576.e6.	1.3	270
171	Dyslipidemia in metabolic syndrome is necessary to elicit severe coronary artery disease and nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2010, 24, 789.5.	0.5	0
172	Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. <i>Gastroenterology</i> , 2008, 135, 1924-1934.e4.	1.3	748
173	Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008, 48, 829-834.	3.7	194
174	Are there ethnicity-based differences in the evaluation of individuals with abnormal liver biochemistries?. <i>Journal of Hepatology</i> , 2007, 47, 123-127.	3.7	5
175	Glycosylphosphatidylinositol-Specific Phospholipase D in Nonalcoholic Fatty Liver Disease: A Preliminary Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2279-2285.	3.6	28
176	Statins and hepatotoxicity: Focus on patients with fatty liver. <i>Hepatology</i> , 2005, 41, 690-695.	7.3	243
177	Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes. <i>American Journal of Gastroenterology</i> , 2005, 100, 1317-1321.	0.4	28
178	Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. <i>Gastroenterology</i> , 2004, 126, 1287-1292.	1.3	375
179	Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1497-1502.	0.4	307
180	Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2003, 37, 544-550.	7.3	296

#	ARTICLE	IF	CITATIONS
181	Does Leptin Play A Role in The Pathogenesis of Human Nonalcoholic Steatohepatitis?. American Journal of Gastroenterology, 2003, 98, 2771-2776.	0.4	123
182	Improved Patient Survival After Acute Variceal Bleeding: A Multicenter, Cohort Study. American Journal of Gastroenterology, 2003, 98, 653-659.	0.4	352
183	Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology, 2003, 98, 1849-1855.	0.4	62
184	A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology, 2001, 33, 802-807.	7.3	267
185	Effects of Albumin/Furosemide Mixtures on Responses to Furosemide in Hypoalbuminemic Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 1010-1016.	6.1	86
186	Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology, 2000, 31, 7-11.	7.3	328